用一种菲甲醇（WR 33063）和一种喹啉甲醇（WR 30090）治疗来自越南的恶性疟。
Treatment of falciparum malaria from Vietnam with a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090).
作者信息
Canfield C J, Hall A P, MacDonald B S, Neuman D A, Shaw J A
出版信息
Antimicrob Agents Chemother. 1973 Feb;3(2):224-7. doi: 10.1128/AAC.3.2.224.
Two new investigational antimalarial drugs developed by the U.S. Army Malaria Research Program were tested in patients with multi-drug-resistant falciparum malaria from Vietnam. WR 33063, a phenanthrene methanol, cured 13 patients treated in the United States. All of these patients had suffered multiple recrudescences after treatment with standard antimalarial drugs. In addition, 23 of 25 patients with acute attacks of falciparum malaria treated in Vietnam were cured. The rate of clinical response was prompt. WR 30090, a quinoline methanol, similarly cured eight patients with multiple recrudescences in the United States and 23 of 26 patients in Vietnam. Adverse effects associated with the drugs were not seen. These drugs signify a major advance in the chemotherapy of drug-resistant falciparum malaria.
美国陆军疟疾研究项目研发的两种新型抗疟药物在来自越南的多重耐药恶性疟患者身上进行了测试。菲并甲醇WR 33063治愈了在美国接受治疗的13名患者。所有这些患者在使用标准抗疟药物治疗后都出现了多次复发。此外，在越南接受治疗的25名恶性疟急性发作患者中有23名被治愈。临床反应迅速。喹啉甲醇WR 30090同样治愈了在美国的8名多次复发患者以及在越南的26名患者中的23名。未观察到与这些药物相关的不良反应。这些药物标志着耐药恶性疟化疗方面的一项重大进展。
Zotero 插件